Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 
• By Anju Ghangurde

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Parexel leadership
(R) Peyton Howell, CEO, Parexel and (L) Sanjay Vyas, President and MD, Parexel India

More from India

More from ESG